ClinicalTrials.gg
Active, not recruitingNCT06834360CEREN-2Updated Oct 21, 2026

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

A Phase 3 interventional study of Itepekimab (SAR440340) and Placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Sanofi. Active, not recruiting at 111 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Nasal Polyps by Sanofi — none open to participants now, 4 under way, 3 of them phase 3. Nasal Polyps · Sanofi.

Enrollment
4th of 12
216 · median 69
Started
2025
with 2 others
Phase 3
7 of 13
none open now
Registered
9th of 13
by date

Among the 13 studies in Nasal Polyps by Sanofi, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 in phase 3, and was the 9th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

None of the 13 studies in Nasal Polyps by Sanofi is open now. The open studies under Nasal Polyps, anywhere →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Nasal Polyps by Sanofi as a file.
02

Study summary

EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older.

Study details include:

  • The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks.
  • The treatment duration will be up to 52 weeks.
  • The number of visits will be 9 site visits and 20 phone/home visits.
03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years of age or older.
  • Participants with a history of chronic rhinosinusitis with nasal polyps (CRSwNP) for at least 1 year prior to screening
  • Participants must have at least one of the following features:

    • Prior sinonasal surgery for nasal polyps (NP).
    • Worsening symptoms of chronic rhinosinusitis (CRS) requiring treatment with systemic (s) (SCS) within the prior 1 year before screening (Visit 1).
  • An endoscopic bilateral Nasal Polyp Score (NPS) of at least 5 out of maximum score of 8 (with a minimum score of 2 in each nasal cavity) at screening and randomization.
  • Ongoing symptoms (for at least 12 weeks before Visit 1) of:

    • Nasal congestion/blockade/obstruction with moderate or severe (symptom severity score 2 or 3) at Visit 1 and a weekly average severity of greater than 1 in the week before randomization (Visit 2), AND
    • At least one of the following two symptoms: loss of smell or rhinorrhea (anterior/posterior).
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

    • Is not a women of (WOCBP), OR
    • Is a WOCBP and agrees to use a method that is highly effective, with a failure rate of \<1% during the study (at a minimum until 20 weeks after the last dose of study intervention).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participants with a history of renal, hepatic, metabolic, neurologic, hematologic, ophthalmologic, respiratory (excluding those with asthma and aspirin-exacerbated respiratory disease (AERD) which may be included in the study), gastrointestinal, cardiovascular, cerebrovascular, or other significant medical illness or disorder, which, in the judgment of the Investigator, could interfere with the study or require treatment that might interfere with the study.
  • Participants who are currently smoking tobacco and/or vaping, or participants in whom smoking/vaping cessation has occurred \<6 months prior to Screening (Visit 1). Nicotine replacement therapy and/or noninhaled tobacco product use are not considered current smoking of tobacco.
  • Participants meet any for mometasone furoate nasal spray (MFNS) such as to MFNS or any of its components; or participants with uncontrolled opportunistic infections.
  • Participants with a history of a severe systemic hypersensitivity reaction to a mAb.
  • Participants with conditions/concomitant diseases making them non-evaluable at Visit 1 or for the primary efficacy endpoint.
  • Participants with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc).
  • Participants with severe uncontrolled asthma with history of 2 and/or more exacerbations, requiring SCS or 1 hospitalization requiring SCS in the past year.
  • History of concomitant lung disease (other than asthma, eg, , interstitial lung disease) which in the opinion of the Investigator could interfere with performance and interpretation of spirometry.
  • Participants treated with intranasal (s) (INCS) (MFNS is permitted), intranasal emitting devices/stents, nasal spray using exhalation delivery system such as XhanceTM during the screening period. In Japan and China INCS other than MFNS are permitted.
  • Participants who have undergone any sinus intranasal surgery (including polypectomy) within 6 months before Visit 1.
  • Participants who received SCS 1 month prior to Screening (Visit 1) or during the screening period (between Visit 1 and Visit 2).
  • Known allergy to itepekimab or its , or any drug or other allergy that, in the opinion of the Investigator, contraindicates participation in this study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Itepekimab high dose

    Subcutaneous (SC) administration of Itepekimab high dose for 52 weeks

    Drug: Itepekimab (SAR440340) · Drug: Mometasone furoate nasal spray (MFNS)

  • Experimental
    Itepekimab low dose

    SC administration of Itepekimab low dose for 52 weeks

    Drug: Itepekimab (SAR440340) · Drug: Placebo · Drug: Mometasone furoate nasal spray (MFNS)

  • Placebo comparator
    Placebo

    SC administration of matching placebo for 52 weeks

    Drug: Placebo · Drug: Mometasone furoate nasal spray (MFNS)

Interventions

  • Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

    Also known as: REGN3500

  • DrugPlacebo

    Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

  • Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray

06

What researchers measure

Primary outcomes

  1. Change from baseline in the endoscopic NPS

    The Nasal Polyp Score (NPS) is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).

    Time frame: Baseline to Week 24

  2. Change from baseline in the NCS

    The Nasal Congestion Score (NCS) is scored using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Outcome value is defined as the preceding 28-day average of morning scores recorded in eDiary.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change from baseline in endoscopic NPS

    The NPS is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).

    Time frame: Baseline to Week 52

  2. Change from baseline in NCS

    The NCS is scored using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Outcome value is defined as the preceding 28-day average of morning scores recorded in eDiary.

    Time frame: Baseline to Week 52

  3. Change from baseline in opacification of sinuses assessed by Computed Tomography (CT) scan using the LMK score

    The Lund-Mackay (LMK) system is based on localization with points given for degree of opacification: 0 = normal, 1 = partial opacification, 2 = total opacification. These points are then applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side. The osteomeatal complex is graded as 0 = not occluded, or 2 = occluded, deriving a maximum score of 12 per side. The total score is the sum of scores from each side and ranges from 0 (normal) to 24 (total opacification).

    Time frame: Baseline to Week 24

  4. Change from baseline in the TSS (nasal congestion/obstruction, anterior/posterior rhinorrhea, and loss of sense of smell)

    The CRSwNP Total Symptom Score (TSS) is a composite score derived from nasal congestion (NC)/obstruction, anterior/posterior rhinorrhea, and loss of smell. The total score ranges from 0 to 9 with higher scores on TSS indicating greater overall symptom severity.

    Time frame: Baseline to Weeks 24 and 52

  5. Change from baseline in loss of smell severity score using the daily CRSwNP sinonasal symptom eDiary, and UPSIT score

    The CRSwNP sinonasal symptom diary is designed to assess the severity of chronic rhinosinusitis (CRS) sinonasal symptoms on daily basis. These symptoms include NC/obstruction, anterior rhinorrhea and posterior rhinorrhea, facial pain/pressure, loss of smell, and headache. Each of the individual items of the diary are scored from 0 ("No symptoms") to 3 ("Severe symptoms - symptoms that are hard to tolerate, cause interference with activities or daily living"). Higher scores on the items of the individual symptoms denote greater symptom severity. The University of Pennsylvania Smell Identification Test (UPSIT) test is a rapid and easy-to-administer method to quantitatively assess human olfactory function. The total score ranges from 0 (anosmia) to 40 (normosmia).

    Time frame: Baseline to Weeks 24 and 52

  6. Change from baseline in SNOT-22 total score

    The Sino-Nasal Outcome Test-22-Items (SNOT-22) is a patient-reported outcome questionnaire designed to assess the impact of CRS on patient's Health-Related Quality of Life (HRQoL). It has 22 items covering five domains: Nasal, Ear/Facial, Sleep, Function, and Emotion. A global score ranging from 0 to 110 with higher score indicating greater rhinosinusitis related health burden.

    Time frame: Baseline to Weeks 24 and 52

  7. Change from baseline in PROMIS SD-SF-8b scores

    The Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form 8b (SD-SF-8b) is a generic 8-item sleep disturbance assessment that evaluates difficulties with falling asleep, staying asleep, and getting enough sleep; and perceptions on the quality and satisfaction of sleep. Scores are calculated with a conversion of the raw score (score range 8 to 40) into a standardized T-score with the mean of the 50 and SD of 10, where higher scores indicate more disturbed sleep.

    Time frame: Baseline to Weeks 24 and 52

  8. Proportion of participants with CRSwNP requiring systemic corticosteroid(s) (SCS) or surgery for CRS

    Time frame: Baseline up to Week 52

  9. Annualized rate of SCS course or surgery for CRS

    Time frame: Baseline up to Week 52

  10. Time to first either SCS or surgery for CRS

    Time frame: Baseline through Week 52

  11. Change from baseline in pre-BD FEV1 (in mL) in participants with co-morbid asthma

    Pre-BD FEV1: pre-bronchodilator forced expiratory volume in 1 second

    Time frame: Baseline to Weeks 24 and 52

  12. Change from baseline in ACQ-5 score in participants with co-morbid asthma

    The Asthma Control Questionnaire (ACQ) is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has 5 questions on the asthma symptoms. The global score is the mean of the item responses and ranges from 0 and 6 with higher score indicating lower asthma control.

    Time frame: Baseline to Weeks 24 and 52

  13. Change from the baseline in NPS and NCS in the subgroup of patients with aspirin-exacerbated respiratory disease (AERD)

    Time frame: Baseline to Weeks 24 and 52

  14. Proportion of participants with AERD requiring SCS or surgery for CRS

    Time frame: Baseline up to Week 52

  15. Annualized rate of SCS course or surgery for CRS in participants with AERD

    Time frame: Baseline up to Week 52

  16. Time to first either SCS or surgery for CRS in participants with AERD

    Time frame: Baseline through Week 52

  17. Change from baseline in pre-BD FEV1 (in ml) in participants with AERD

    Pre-BD FEV1: pre-bronchodilator forced expiratory volume in 1 second

    Time frame: Baseline to Weeks 24 and 52

  18. Proportion of NPS responders (defined as participants with improvement by at least 1 point in NPS)

    Time frame: Weeks 24 and 52

  19. Proportion of NPS responders (defined as participants with improvement by at least 2 points in NPS)

    Time frame: Weeks 24 and 52

  20. Incidence of treatment-emergent adverse Events (TEAEs), treatment-emergent serious adverse events (TESAEs), treatment-emergent adverse events of special interest (TEAESIs) and TEAEs leading to treatment discontinuation

    Time frame: Baseline to End of Study (EOS) (Week 72)

  21. Itepekimab concentration in serum

    Time frame: Baseline to EOS (Week 72)

  22. Incidence of treatment-emergent anti-itepekimab antibody (ADA) responses

    Time frame: Baseline to EOS (Week 72)

07

Study locations

111 sites
  • Excel ENT of Alabama- Site Number : 8400052
    Birmingham, Alabama 35244, United States
  • Velocity Clinical Research - San Diego- Site Number : 8400041
    La Mesa, California 91942, United States
  • Cedars-Sinai Medical Center- Site Number : 8400030
    Los Angeles, California 90048, United States
  • One Of A Kind Clinical Research Center- Site Number : 8400034
    Napa, California 94558, United States
  • University of Florida - Jacksonville- Site Number : 8400053
    Jacksonville, Florida 32209, United States
  • Advanced Research Institute - New Port Richey- Site Number : 8400014
    New Port Richey, Florida 34653, United States
  • University of Illinois at Chicago- Site Number : 8400003
    Chicago, Illinois 60607, United States
  • Advanced ENT & Allergy - Louisville- Site Number : 8400007
    Louisville, Kentucky 40220, United States
  • Velocity Clinical Research - Lafayette- Site Number : 8400026
    Lafayette, Louisiana 70508, United States
  • Johns Hopkins Hospital- Site Number : 8400017
    Baltimore, Maryland 21287, United States
  • University of Cincinnati Medical Center- Site Number : 8400022
    Cincinnati, Ohio 45219, United States
  • Allergy, Asthma and Clinical Research- Site Number : 8400002
    Oklahoma City, Oklahoma 73120, United States
  • Thomas Jefferson University Hospital- Site Number : 8400044
    Philadelphia, Pennsylvania 19107, United States
  • Spartanburg-Greer ENT & Allergy- Site Number : 8400039
    Greer, South Carolina 29650, United States
  • Ear and Sinus Institute- Site Number : 8400048
    Fort Worth, Texas 76104, United States
  • Investigational Site Number : 0320005
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1414, Argentina
  • Investigational Site Number : 0320004
    Corrientes, 3400, Argentina
  • Investigational Site Number : 0320003
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0360003
    Bella Vista, New South Wales 2153, Australia
  • Investigational Site Number : 0360002
    Brisbane, Queensland 4029, Australia
  • Investigational Site Number : 0360001
    Spearwood, Western Australia 6163, Australia
  • Investigational Site Number : 0560004
    Gesves, Namur 5340, Belgium
  • Investigational Site Number : 0560006
    Alken, 3570, Belgium
  • Investigational Site Number : 0560002
    Ghent, 9000, Belgium
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Private Practice - Dr. Nelson Rosário- Site Number : 0760001
    Curitiba, Paraná 80810-100, Brazil
  • Centro de Pesquisa Clínica de Marília - CPCLIM- Site Number : 0760002
    Marília, São Paulo 17504-072, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760005
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Clinica de Alergia Martti Antila- Site Number : 0760003
    Sorocaba, São Paulo 18040-425, Brazil
  • Investigational Site Number : 1240017
    Vancouver, British Columbia V6A 2W1, Canada
  • Investigational Site Number : 1240019
    Burlington, Ontario L7R 3P9, Canada
  • Investigational Site Number : 1240015
    Cambridge, Ontario N1R 8L4, Canada
  • Investigational Site Number : 1240014
    Ottawa, Ontario K1G 6C6, Canada
  • Investigational Site Number : 1240003
    Québec, Quebec G1V 4W2, Canada
  • Investigational Site Number : 1240012
    Québec, Quebec G2J 0C4, Canada
  • Investigational Site Number : 1520001
    Concepción, Biobio 4070094, Chile
  • Investigational Site Number : 1520004
    Talcahuano, Biobio 2687000, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7500505, Chile
  • Investigational Site Number : 1520002
    Quillota, Valparaiso 2260877, Chile
  • Investigational Site Number : 1560020
    Baotou, 014040, China
  • Investigational Site Number : 1560001
    Beijing, 100730, China
  • Investigational Site Number : 1560004
    Chengdu, 610017, China
  • Investigational Site Number : 1560025
    Chongqing, 400016, China
  • Investigational Site Number : 1560019
    Hangzhou, 310003, China
  • Investigational Site Number : 1560002
    Jinan, 250022, China
  • Investigational Site Number : 1560012
    Jingzhou, 434020, China
  • Investigational Site Number : 1560021
    Nanning, 530021, China
  • Investigational Site Number : 1560006
    Shenyang, 110004, China
  • Investigational Site Number : 1560024
    Suzhou, 215006, China
  • Investigational Site Number : 1560017
    Taiyuan, 030001, China
  • Investigational Site Number : 1560023
    Taiyuan, 030001, China
  • Investigational Site Number : 1560014
    Wuhan, 430060, China
  • Investigational Site Number : 1560003
    Yantai, 264001, China
  • Investigational Site Number : 1560009
    Zibo, 255036, China
  • Investigational Site Number : 2030002
    Hradec Králové, 500 05, Czechia
  • Investigational Site Number : 2030003
    Pardubice, 532 03, Czechia
  • Investigational Site Number : 2030005
    Pilsen, 305 99, Czechia
  • Investigational Site Number : 2030004
    Prague, 100 34, Czechia
  • Investigational Site Number : 2030001
    Prague, 150 06, Czechia
  • Investigational Site Number : 2080001
    Aarhus, 8200, Denmark
  • Investigational Site Number : 2080004
    Copenhagen, 2100, Denmark
  • Investigational Site Number : 2080002
    Køge, 4600, Denmark
  • Investigational Site Number : 2500011
    Bordeaux, 33076, France
  • Investigational Site Number : 2500004
    Marseille, 13005, France
  • Investigational Site Number : 2500001
    Nantes, 44093, France
  • Investigational Site Number : 2500010
    Poitiers, 86021, France
  • Investigational Site Number : 2500014
    Pontoise, 95300, France
  • Investigational Site Number : 2500007
    Toulouse, 31059, France
  • Investigational Site Number : 2760006
    Dresden, 01139, Germany
  • Investigational Site Number : 2760001
    Dresden, 01307, Germany
  • Investigational Site Number : 2760005
    Hamburg, 20246, Germany
  • Investigational Site Number : 2760002
    Leipzig, 04103, Germany
  • Investigational Site Number : 2760007
    Mainz, 55131, Germany
  • Investigational Site Number : 2760008
    Villingen-Schwenningen, 78052, Germany
  • Investigational Site Number : 3480005
    Budapest, 1026, Hungary
  • Investigational Site Number : 3480001
    Szeged, 6720, Hungary
  • Investigational Site Number : 3760003
    Haifa, 3104802, Israel
  • Investigational Site Number : 3760004
    Jerusalem, 9112001, Israel
  • Investigational Site Number : 3760001
    Nahariya, 2210001, Israel
  • Investigational Site Number : 3760002
    Rehovot, 7610001, Israel
  • Investigational Site Number : 3800001
    Milan, Milano 20132, Italy
  • Investigational Site Number : 3800005
    Naples, Napoli 80131, Italy
  • Investigational Site Number : 3800003
    Catania, 95123, Italy
  • Investigational Site Number : 2500005
    Toyama, 939-2716, Japan
  • Investigational Site Number : 4840001
    Guadalajara, Jalisco 44100, Mexico
  • Investigational Site Number : 4840008
    Monterrey, Nuevo León 64718, Mexico
  • Investigational Site Number : 4840007
    Chihuahua City, 31217, Mexico
  • Investigational Site Number : 4840002
    Veracruz, 91900, Mexico
  • Investigational Site Number : 5280002
    Amsterdam, 1081 HV, Netherlands
  • Investigational Site Number : 5280001
    Utrecht, 3584 CX, Netherlands
  • Investigational Site Number : 6160004
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • Investigational Site Number : 6160005
    Wroclaw, Lower Silesian Voivodeship 50-750, Poland
  • Investigational Site Number : 6160002
    Lodz, Lódzkie 90-302, Poland
  • Investigational Site Number : 6160001
    Bielsko-Biala, Silesian Voivodeship 43-300, Poland
  • Investigational Site Number : 6420003
    Brasov, 500091, Romania
  • Investigational Site Number : 6420002
    Brasov, 500283, Romania
  • Investigational Site Number : 6420001
    Bucharest, 022328, Romania
  • Investigational Site Number : 7240006
    Barcelona, Barcelona [Barcelona] 08003, Spain

Showing the first 100 of 111 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2026, 19 months.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 19 months is below that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Nov 2026 → Sep 2026 and completion Oct 2027 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 19, 2025
StartActual
Feb 6, 2025
Primary completionActual
Sep 24, 2026was Nov 2026
CompletionEst.
Feb 17, 2027was Oct 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 6, 2026→Sep 24, 2026 (actual)
Oct 21, 2026
Study completion
Oct 11, 2027→Feb 17, 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Nov 6, 2026→Sep 24, 2026 (now actual)
    Study completion Oct 11, 2027→Feb 17, 2027
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06834360
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Feb 6, 2025
Primary completion
Sep 24, 2026
Completion
Feb 17, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion